Radiofrequency plasma treated polymeric surfaces having immobilized anti-thrombogenic agents
AssigneeCordis Corporation
InventorsPallassana V. Narayanan, Kimberly D. Stanley
Life of this patent
Estimating the term…
Abstract
Polymeric surfaces of medical devices or components of medical devices are provided that have enhanced biocompatibility properties. The polymeric surface presents an anti-thrombogenic, fibrinolytic or thrombolytic interface with body fluids such as blood during implantation or medical procedures. The biocompatibility enhancing agent is secured to the polymeric substrate by a spacer molecule which is covalently bound to the polymeric substrate which had been subjected to radiofrequency plasma treatment with a water vapor medium.
Claims14
A method for enhancing the biocompatibility of medical device polymeric surfaces, comprising the steps of:
- positioning a polymeric surface within a radiofrequency plasma discharge environment;
- inserting fluid into said radiofrequency plasma discharge environment to provide plasma medium having between about 40 and about 90 volume percent water vapor, the balance of said fluid, between about 10 and about 60 volume percent being oxygen, based on the total volume of the plasma medium;
- subjecting said plasma medium within the environment to radiofrequency electric field in order to form reactive species from said fluid within the environment and to have the reactive species react with the polymeric surface to form a modified polymeric surface having reactive sites;
- treating said modified polymeric surface with a spacer component having amine groups, said treating step being in the presence of a coupling agent, whereby covalent linkages are formed between the spacer component amine groups and the reactive sites of the modified polymeric surface;
- and
- contacting an anti-thrombogenic, fibrinolytic or thrombolytic agent having acid functionality and biologically active properties with said spacer component-treated modified polymeric surface, whereby said medical device polymeric surface exhibits biocompatibility improvements over said polymeric surface which is not treated according to the method, and whereby said biocompatible medical device polymeric surface anti-thrombogenic, fibrinolytic or thrombolytic agent is resistant to extraction under in vivo conditions while retaining its biologically active properties.
A method for enhancing the biocompatibility of medical device polymeric surfaces, comprising the steps of:
- positioning a polymeric surface within a radiofrequency plasma discharge environment;
- inserting fluid into said radiofrequency plasma discharge environment to provide a plasma medium having between about 40 and about 100 volume percent water vapor and between about 0 and about 60 volume percent oxygen, based on the total volume of the plasma medium;
- subjecting said plasma medium within the environment to a radiofrequency electric field in order to form reactive species from said fluid within the environment and to have the reactive species react with the polymeric surface to form a modified polymeric surface having reactive sites;
- treating said modified polymeric surface with a spacer component having amine groups, said treating step being in the presence of a coupling agent, whereby covalent linkages are formed between the spacer component amine groups and the reactive sites of the modified polymeric surface;
- contacting an anti-thrombogenic, fibrinolytic or thrombolytic agent having acid funtionality and biologically active properties with said spacer component-treated modified polymeric surface, whereby said medical device polymeric surface exhibits biocompatibility improvement over said polymeric surface which is not treated according to the method, and whereby said biocompatible medical device polymeric surface anti-thrombogenic, fibrinolytic or thrombolytic agent is resistant to extraction under in vivo conditions while retaining its biologically active properties;
- and
- said positioning step is preceded by pretreating a silicone rubber polymeric surface with an inert gas plasma procedure.
A medical device having a biocompatible polymeric surface, wherein said biocompatible polymeric surface comprises a surface which has been modified by subjecting the polymeric surface to radiofrequency discharge treatment within a plasma medium having between about 40 and about 90 volume percent water vapor, the balance of said plasma medium being between about 10 and about 60 volume percent oxygen based upon the total volume of plasma medium, followed by treatment with a coupling agent and a spacer component having amine groups forming covalent linkages with the polymeric surfaces which had been subjected to radiofrequency discharge treatment with said plasma medium, and then by treatment with an anti-thrombogenic, fibrinolytic or thrombolytic agent having acid functionality contacting and covalently bonding with the spacer component-treated polymeric surface to provide the biocompatible polymeric surface.
A medical device having a biocompatible polymeric surface, wherein said biocompatible polymeric surface comprises a surface which has been modified by subjecting the polymeric surface to radiofrequency discharge treatment within a plasma medium having at least about 40 volume percent water vapor, based upon the total volume of plasma medium, followed by treatment with a coupling agent and a spacer component having amine groups forming covalent linkages with the polymeric surface which had been subjected to radiofrequency discharge treatment with said plasma medium, and then by treatment with an anti-thrombogenic, fibrinolytic or thrombolytic agent having acid functionality contacting and covalently bonding with the spacer component-treated polymeric surface to provide the biocompatible polymeric surface, and said polymeric surface is a silicone rubber surface that had been pretreated with an inert gas plasma.
Dependencies are inferred from the claim text.